WO2004010936A3 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders - Google Patents

Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders Download PDF

Info

Publication number
WO2004010936A3
WO2004010936A3 PCT/US2003/023430 US0323430W WO2004010936A3 WO 2004010936 A3 WO2004010936 A3 WO 2004010936A3 US 0323430 W US0323430 W US 0323430W WO 2004010936 A3 WO2004010936 A3 WO 2004010936A3
Authority
WO
WIPO (PCT)
Prior art keywords
dyslipidemia
treatment
lipid disorders
ppar alpha
selective compounds
Prior art date
Application number
PCT/US2003/023430
Other languages
French (fr)
Other versions
WO2004010936A2 (en
Inventor
Guo Q Shi
Yong Zhang
Original Assignee
Merck & Co Inc
Guo Q Shi
Yong Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Guo Q Shi, Yong Zhang filed Critical Merck & Co Inc
Priority to EP03771907A priority Critical patent/EP1539136B1/en
Priority to JP2004524883A priority patent/JP4475406B2/en
Priority to DE60322075T priority patent/DE60322075D1/en
Priority to US10/522,259 priority patent/US7524882B2/en
Priority to AU2003256842A priority patent/AU2003256842B8/en
Priority to CA002491733A priority patent/CA2491733A1/en
Publication of WO2004010936A2 publication Critical patent/WO2004010936A2/en
Publication of WO2004010936A3 publication Critical patent/WO2004010936A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Abstract

A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.
PCT/US2003/023430 2002-07-30 2003-07-25 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders WO2004010936A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03771907A EP1539136B1 (en) 2002-07-30 2003-07-25 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
JP2004524883A JP4475406B2 (en) 2002-07-30 2003-07-25 PPARα selective compounds for the treatment of dyslipidemia and other lipid disorders
DE60322075T DE60322075D1 (en) 2002-07-30 2003-07-25 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
US10/522,259 US7524882B2 (en) 2002-07-30 2003-07-25 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
AU2003256842A AU2003256842B8 (en) 2002-07-30 2003-07-25 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
CA002491733A CA2491733A1 (en) 2002-07-30 2003-07-25 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39952002P 2002-07-30 2002-07-30
US60/399,520 2002-07-30

Publications (2)

Publication Number Publication Date
WO2004010936A2 WO2004010936A2 (en) 2004-02-05
WO2004010936A3 true WO2004010936A3 (en) 2004-08-26

Family

ID=31188592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023430 WO2004010936A2 (en) 2002-07-30 2003-07-25 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Country Status (8)

Country Link
US (1) US7524882B2 (en)
EP (1) EP1539136B1 (en)
JP (1) JP4475406B2 (en)
AT (1) ATE400564T1 (en)
AU (1) AU2003256842B8 (en)
CA (1) CA2491733A1 (en)
DE (1) DE60322075D1 (en)
WO (1) WO2004010936A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491733A1 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
WO2004106276A1 (en) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Condensed ring compound
CA2532971A1 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2003267347A1 (en) * 2003-09-10 2005-03-29 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
JPWO2006016637A1 (en) * 2004-08-11 2008-05-01 杏林製薬株式会社 New cyclic aminobenzoic acid derivatives
US20090036489A1 (en) * 2005-03-22 2009-02-05 Masahiro Nomura Novel Cyclic Aminophenylalkanoic Acid Derivative
EP2025674A1 (en) * 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
JPWO2009087981A1 (en) * 2008-01-11 2011-05-26 株式会社Kri Polymerizable compound and production method thereof
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014123205A1 (en) 2013-02-06 2014-08-14 住友化学株式会社 Condensed heterocyclic compound
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3310760B8 (en) 2015-06-22 2022-10-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
MA47504A (en) 2017-02-16 2019-12-25 Arena Pharm Inc COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS
CN108546245A (en) * 2018-05-22 2018-09-18 绍兴文理学院 A kind of preparation method of antiproliferative activity intermediate ML-098

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2169893A (en) * 1984-12-28 1986-07-23 Shionogi & Co Benzofuran and benzothiophene derivatives
WO2004010936A2 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205080A (en) * 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
US4213999A (en) * 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
US4213998A (en) * 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
DE3265715D1 (en) * 1981-03-24 1985-10-03 Fisons Plc Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them
FR2645537B1 (en) * 1989-04-05 1994-03-04 Fabre Medicament Pierre NOVEL SULFONAMIDES DERIVED FROM BENZOCYCLIC OR BENZOHETEROCYCLIC ACIDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5352690A (en) * 1992-07-01 1994-10-04 Eli Lilly And Company 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
JP3187611B2 (en) * 1993-05-17 2001-07-11 キヤノン株式会社 Liquid crystal compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using them
US5516917A (en) * 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
EP1347755A2 (en) * 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2169893A (en) * 1984-12-28 1986-07-23 Shionogi & Co Benzofuran and benzothiophene derivatives
WO2004010936A2 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] COHEN ET AL: "3,4-dihydro-@h-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists", XP003001470, accession no. STN Database accession no. 1989:553565 *
J. OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, pages 1842 - 1860 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
JP4475406B2 (en) 2010-06-09
CA2491733A1 (en) 2004-02-05
AU2003256842A1 (en) 2004-02-16
US20050228044A1 (en) 2005-10-13
DE60322075D1 (en) 2008-08-21
EP1539136A2 (en) 2005-06-15
WO2004010936A2 (en) 2004-02-05
EP1539136B1 (en) 2008-07-09
EP1539136A4 (en) 2006-10-18
US7524882B2 (en) 2009-04-28
AU2003256842B2 (en) 2009-02-19
ATE400564T1 (en) 2008-07-15
AU2003256842B8 (en) 2009-06-18
JP2006500335A (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2004010936A3 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
EP1539137A4 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
HUS1400011I1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
BR0109703A (en) Piperazine Derivatives
WO2006033891A3 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
IL165860A0 (en) Administration of therapeutic viruses
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
UY27462A1 (en) QUINOLINE DERIVATIVES
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
TW200732304A (en) Piperidine derivatives
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
SE9902267D0 (en) New compounds
IL143985A0 (en) New use of melagatran
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
WO2008033655A3 (en) Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
SI1534296T1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2491733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003256842

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10522259

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003771907

Country of ref document: EP

Ref document number: 2004524883

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003771907

Country of ref document: EP